The previous article (click here) on Stereotaxis (STXS) concentrated on the substantial valuation discount to its robotic peers and why it appears to be too steep. The speed at which that discount closes will be rapid if, as we suspect, the Company's entry into Japan & US approval of Vdrive return Stereotaxis to year-over-year top line growth in 2014.
As we highlighted in the first article, in this second part of our analysis of Stereotaxis we will discuss the five following points:
- Refinancing of the Healthcare Royalty Partners LP loan, which carries a 16% coupon becomes a real prospect, later this year
- Potential M&A scenarios that could unfold and why it may make sense for another
Only subscribers can access this article, which is part of the PRO research library covering 3,602 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: